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Summary 
Renalase is a recently discovered flavoprotein that regulates blood pressure, sodium 
and phosphate excretion, and has a cardioprotectant action through a mechanism that is 
scarcely understood to date. It has been proposed to act as a catecholamine-degrading 
enzyme, either via O2- or NADH-dependent mechanisms. Here we report the renalase crystal 
structure at 2.5 Å resolution together with new data on its interaction with nicotinamide 
dinucleotides. Renalase adopts the p-hydroxybenzoate hydroxylase fold topology, comprising 
a Rossmann fold based FAD-binding domain, and a putative substrate-binding domain, 
containing a five-stranded antiparallel -sheet. A large cavity (228 Å3), facing the flavin ring, 
presumably represents the active site. Compared to mono- or poly-amine oxidases, the 
renalase active-site is fully solvent exposed and lacks the ‘aromatic cage’ for binding the 
substrate amino-group. Renalase has extremely low diaphorase activity, displaying lower kcat 
but higher kcat/Km for NADH compared to NADPH. Moreover, its FAD prosthetic group 
becomes slowly reduced when it is incubated with NAD(P)H under anaerobiosis, and binds 
NAD+ or NADP+ with Kd values of ca. 2 mM. The absence of a recognizable NAD(P)-
binding site in the protein structure and its poor affinity/reactivity towards NAD(H) and 
NADP(H) suggest that these are not physiological ligands of renalase. Although our study 
does not answer the question of what the catalytic activity of renalase is, it provides a firm 
framework for testing hypotheses on the molecular mechanism of its action. 
 
Keywords: chronic kidney disease, end-stage renal disease, hypertension, phosphate 
excretion, flavoprotein structure. 
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Abbreviations 
MAO, monoamine oxidase; INT, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium 
chloride; WST1, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 
sodium salt; HT, hydride transfer; rmsds, pairwise root-mean-square deviations; PHBH, p-
hydroxybenzoate hydroxylase; DAAO, D-ammino acid oxidase; PAO, polyamine oxidase; 
MR, molecular replacement. 
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Introduction 
Renalase was identified in 2005 in a study focused on new links between chronic 
kidney diseases and their cardiovascular complications.1 The human renalase gene (RNLS) is 
located on chromosome 10 and includes 10 exons.2 Various isoforms arising from alternative 
splicing have been reported, two of which (renalase1 and renalase2) are annotated in genome 
databases (GenBank accession nos. NP_001026879 and NP_060833, respectively). RNLS is 
expressed in kidneys, heart, skeletal muscle, brain and small intestine;3 the main product 
(renalase1) has been detected also in blood plasma and urine.2 End-stage renal disease is 
associated to lowered plasma renalase1 levels, indicating that kidneys are the source of the 
circulating protein.1 Renalase has also been proposed as an early biomarker of acute kidney 
ischemia.4 Intravenous administration of renalase1 was found to decrease blood pressure and 
heart rate in normal rats,1 while its subcutaneous injection had an intense and prolonged 
antihypertensive effect in an animal model of salt-sensitive hypertension,4,5 and its perfusion 
was found to play a heart protective effect in a cardiac ischemia mouse model.2 Furthermore, 
RNLS gene inactivation in mouse resulted in an increased sympathetic activity, tachycardia 
and hypertension.6 Two allelic variants of renalase, displaying similar frequencies in the 
human population, carrying Glu or Asp at position 37, are known. The Asp variant was found 
to correlate significantly with an increased risk of developing essential hypertension and 
cardiac syndromes.7,8 It has been proposed that renalase could modulate the intrarenal 
dopamine system, affecting sodium and phosphate excretion.4,5,9 In a rat model of chronic 
heart failure, the lowered blood renal flow is associated to a decrease in kidney renalase 
synthesis and norepinephrine clearance.10 
Despite its potential impact on treatment of some of the “big killer” diseases in the 
developed world, an understanding of renalase action at the molecular level has not been 
reached yet. Stemming from its sequence similarity to flavin-dependent monoamine oxidases 
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(MAOs), it has been suggested that renalase could be a catecholamine-degrading 
flavoenzyme.1,11,12 Evidence has been provided for two possible catalytic mechanisms: O2-
dependent direct oxidation of the amine substrate (as in the case of MAOs), or its NADH-
dependent degradation, mediated by superoxide radical generation.8 However, the turnover 
rate of renalase seems too low to fully justify its physiological effects; moreover, the actual 
presence of a catecholamine-degrading activity in blood plasma, other than that supported by 
semicarbazide-sensitive amine oxidase, has been excluded by some authors.13 For two recent 
comprehensive reviews on renalase, the reader is referred to Refs. 4 and 14. Renalase is 
highly conserved in mammals, but orthologs are present in protists (Phytophthora infestans 
T30-4; 27% sequence identity), cyanobacteria (Cyanothece sp.; 28% identity), and bacteria 
(Spirosoma linguale; 26% identity), suggesting different biological functions associated with 
similar fold and possibly similar catalyzed reaction (see Fig. 5A). 
With the aim of elucidating its catalytic mechanism, we produced an in vivo folded 
form of human renalase1 in Escherichia coli.15 The recombinant protein was found to contain 
non-covalently bound FAD, thus providing the first direct evidence that it is a flavoprotein. 
Here we present a further step towards the elucidation of its structure-function relationships, 
reporting its three-dimensional structure solved at 2.5 Å resolution. These data, together with 
kinetic and nucleotide-binding studies, provide new hints on the active-site structural 
organization in this intriguing enzyme. 
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Results 
Redox properties and reactivity of the renalase FAD prosthetic group 
Since here we report solely on the properties of human renalase1, we use the term 
“renalase” throughout this paper to indicate this specific isoform, unless otherwise stated. To 
shed light onto renalase enzymatic activity, we investigated the stability and protonation state 
of the semiquinone form of its FAD cofactor, which are important criteria for flavoprotein 
classification.16,17 Anaerobic renalase solutions were subjected to stepwise photoreduction at 
different pH values, and the resulting absorption spectra recorded. As shown in Fig. 1, the 
bound FAD could be readily reduced by the light/EDTA/deazariboflavin system, and was 
reoxidized to yield the original spectrum when the solution was exposed to air. More 
interestingly, at acidic pH, a significant amount of a species displaying a broad absorption 
band in the 550-650 nm region, identifiable as neutral flavin semiquinone, was formed during 
reduction. Above pH 7, the FAD blue semiquinone was undetectable (Fig. 1, inset), without 
clear evidence of accumulation of its red anionic form. This behavior is at variance from what 
is observed for both MAO-A and MAO-B, as well as for their homolog from Aspergillus 
niger (MAO-N, containing a noncovalently-bound FAD), which strongly stabilize the FAD 
anionic semiquinone.18,19 
FAD reactivity with sulfite is a distinct key criterion for flavoenzyme classification, 
since a high stability of the sulfite-isoalloxazine adduct usually correlates with a high O2-
reactivity.20 Renalase was found to react with sodium sulfite yielding a complex with a Kd of 
1.8 ± 0.2 mM (Fig. 2). The reaction was found to be very slow, with constants for complex 
formation and dissociation of 0.056 ± 0.007 min-1 and 0.025 ± 0.003 min-1mM-1, respectively. 
Again, these results suggest both that renalase is not a typical oxidase, and that it differs 
dramatically from MAOs, which do not react at all with sulfite due to hydrophobicity of their 
active sites.21 
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Reactivity of renalase with nicotinamide dinucleotides 
Renalase has been reported to catalyze slow O2 reduction in the presence of NADH 
yielding the superoxide radical.8 Since such NADH oxidase reaction suggests the possibility 
that renalase could be either a dehydrogenase or a monooxygenase, we studied in detail its 
NAD(P)H-dependent diaphorase activities using various artificial electron acceptors, such as 
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium chloride (INT), 2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium sodium salt (WST1) and 
K3Fe(CN)6. The recombinant form of renalase we have previously produced in E. coli
15 
corresponds to its Asp37 variant. Since this variant has been reported to possess a lower 
catalytic activity than the Glu37 form,8 we have introduced the Asp37Glu replacement in the 
protein by site-directed mutagenesis. The two variants of renalase displayed indistinguishable 
catalytic properties in vitro. As the Asp37 variant yielded crystals suitable for X-ray analysis, 
here we focus on the properties of this form. 
Renalase displayed a low but measurable catalytic activity only vs. INT and WST1, 
the former substrate being the preferred one. Plots of the steady-state kinetic data for the INT-
reductase reactions are shown in Fig. 3. The steady-state kinetic parameters (Table 1) show 
that renalase is slightly but significantly more specific for NADH rather than NADPH, 
although it displays a higher kcat value with the latter cosubstrate. The reductive half-reaction 
of the catalytic cycle, i.e. the reduction of protein-bound FAD by NAD(P)H, was investigated 
under anaerobic conditions. Both nucleotides were able to transfer reducing equivalents to the 
renalase prosthetic group. Apparent first-order rate constants (kred) for hydride transfer (HT) 
of 1.5×10-2 ± 2×10-4 min-1 and 2.7×10-2 ± 1×10-4 min-1, were obtained for 1 mM NADH 
(kred
NADH) and NADPH (kred
NADPH), respectively. 
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In order to further investigate the interaction of the protein with nicotinamide 
dinucleotides, spectrophotometric titrations of renalase with NAD(P)+ were performed. As 
shown in Fig. 4, renalase clearly interacts with both dinucleotides, forming complexes whose 
remarkably strong difference absorption spectra are very similar. Titrations follow the 
theoretical curve expected for a 1:1 stoichiometry (Fig. 4, inset). The Kd of the complexes of 
renalase with NAD+ and NADP+ were 2.2 ± 0.1 mM and 1.6 ± 0.1 mM, respectively. 
Interestingly, 2’-P-AMP titration yielded a similar Kd value (1.2 ± 0.3 mM), but a far less 
intense difference spectrum (Fig. 4), implying that the adenylate portion of NADP+ provide 
most of the binding energy, while the nicotinamide moiety plays a main role in the 
perturbation the isoalloxazine environment. However, titration of renalase with up to 6 mM 
5’-AMP did not result in any spectral change, suggesting that a single phosphate group in the 
ligand is not sufficient to provide enough binding energy and/or the ability to perturb 
isoalloxazine upon binding. 
 
Renalase crystal structure 
The crystal structure of renalase was solved through a composite molecular 
replacement approach, and refined at 2.5 Å resolution (Rgen /Rfree = 21.7/26.0%; see Table 
2); two renalase molecules are hosted per asymmetric unit. The two independent molecules 
(A and B) display very similar overall conformations, with a pairwise root-mean-square 
deviations (rmsds) of 0.41 Å calculated over 330 C pairs. A contained contact region (467 
Å2) is observed between the two molecules, in keeping with the monomeric character of 
renalase in solution, shown by previous gel filtration and dynamic light scattering studies.15 
The refined electron density allowed us to model all the protein amino acids, with the 
exception of a few that are localized in the substrate-binding domain: i.e. Ser25 (chain A), 
Lys99-Glu100 (A, B), Asp140 (B), Ser150 (B), Glu201 (B), Lys205-Ile206 (A), Ser236 (B)-
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Glu237 (A, B), Cys300 (B). 
The renalase molecule displays a bean-like elongated shape with the longer axis of 
about 60 Å and the shorter of 35 Å. The two lobes of the bean host respectively the FAD-
binding domain (amino acids 1-42, 109-189, 294-341; Fig 5B, red) and the putative substrate-
binding domain (43-108, 190-294; Fig 5B, blue and green). The two domains are bent 
forming a wide and deep cleft at the center of the protein that, like a belt, runs 
perpendicularly to the protein longest axis. Such crevice (positively charged) crosses the 
protein surface opposite to the partially exposed isoalloxazine ring. The FAD molecule is 
buried within the protein except for part of the isoalloxazine ring (see below), a small portion 
of the adenine ring, and part of the adenosine ribose near the pyrophosphate bridge (located 
next to the mentioned cleft). The FAD-binding domain architecture is based on a Rossman 
fold (as in the glutathione reductase family),22 composed of a six-stranded central-sheet 
(with 321465 topology), surrounded by six -helices, and by an additional three-
stranded mixed -sheet. The putative substrate-binding domain consists of an antiparallel 
five-stranded -sheet surrounded by three -helices and by one -hairpin. Moreover, it 
includes a small subdomain (amino acids 62-108), projecting helix 3 toward the FAD-
binding domain (Fig. 5B, green).  
The general fold of renalase classifies it as a member of the flavoprotein superfamily 
sharing the p-hydroxybenzoate hydroxylase (PHBH) fold topology, which includes both 
oxidase and non-oxidase enzymes.23 Most PHBH-like enzymes catalyzing the oxidation of 
amines belong to one of two possible structural groups: the MAO and the D-amino acid 
oxidase (DAAO) families.24 Renalase is structurally more similar to the MAO-like than to 
DAAO-like enzymes. A search performed through the DALI server 
(http://ekhidna.biocenter.helsinki.fi/dali_server/) for proteins structurally homologous to 
renalase yielded a putative protoporphyrinogen oxidase (PDB ID: 3LOV, Z-score 28.9, 
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residue identity 19%), in addition to L-amino acid oxidase, a Lys-specific histone 
demethylase, and an amine oxidase (PDB IDs 2JB2, 2UXX, and 2BXR, respectively). 
With the exception of histone demethylase, the main feature common to all the protein 
structures highlighted by DALI as structurally similar to renalase is the presence of an 
additional stretch of 110-140 amino acids that is entirely absent in renalase (Fig. 6A, left). 
This structural element corresponds to an additional domain that would be inserted between 
strands 7 and 8 of renalase substrate-binding domain. Multiple alignment shows that the 
regions flanking such ‘missing’ domain are not conserved (Fig. 5A). Interestingly, one of the 
short segments disordered in the renalase crystal structure corresponds exactly to the insertion 
point of the ‘missing’ domain (Lys99-Glu100). The functional roles played by this domain in 
the renalase homologs are markedly different: in protoporphyrinogen oxidase it is a 
membrane-binding domain, while in L-amino acid oxidase it is a helical domain responsible 
for protein dimerization. On the contrary, in MAOs and polyamine oxidase (PAO) it is an 
integral part of the substrate-binding domain. 
 
FAD binding 
Nineteen residues are directly involved in FAD binding, six of which establish 
electrostatic or polar interactions with the cofactor (Fig. 6B). Only two of the latter 
interactions involve side chain atoms (conserved residues Thr12 and Arg42 linked to the 
FAD pyrophosphate), the others being due to main chain atoms. Access to the 
dimethylbenzene moiety of the isoalloxazine ring is blocked by the conserved Trp288, while 
the cofactor pyrimidine ring is quite solvent exposed (Fig. 6A, right), establishing hydrogen 
bonds with the main chain atoms of Tyr62 and Phe324 and displaying van der Waals 
interactions with Ala59. 
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Putative substrate-binding site 
The absence of the ‘missing’ domain in renalase (see above) results in the presence of 
a wide surface concavity that is the entry site for the enzyme main core cavity, where the 
FAD cofactor is hosted (Fig. 6A, right). As a consequence, the putative enzyme active site is 
solvent exposed, as underscored by the presence of five water molecules above the 
isoalloxazine ring. The active site cavity has a volume of about 224 Å3 and can be roughly 
divided into two hemispheres, one composed of aromatic residues, the other of polar residues, 
centered on the isoalloxazine ring. The aromatic hemisphere (roughly above the isoalloxazine 
pyrimidine ring) is characterized by residues Tyr62 (mostly conserved), Tyr214 and Phe223 
(aromaticity conserved), the two Tyr residues being mutually hydrogen-bonded (2.7±0.2 Å; 
mean of the two subunits). The polar hemisphere is lined by Gln292, Arg193, His245 (mostly 
conserved) and Arg222, and displays an overall positive charge (Fig. 6B). The water 
molecules found in the cavity bridge between the two sides but their locations are not 
conserved in the two renalase chains, suggesting that the site is suited to accommodate polar 
compounds. A sulphate anion, hydrogen-bonded to Thr247, and electrostatically 
compensated by Arg193 and Arg222, is present in both asymmetric unit renalase molecules, 
at the external border of the polar cavity (Fig. 6B). Since renalase has been proposed to 
represent a new form of MAO,1,11 a structural comparison with the active site of the latter 
enzyme is useful. The overlay of the three-dimensional structure of renalase with those of 
MAO A, MAO B and PAO led to the observation that the position of the active-site cavity is 
highly conserved in all these enzymes. However, residues critical for catalysis of amine 
oxidation are not maintained in renalase. In particular, Lys296 (MAO B numbering), is 
replaced by His245, and the so-called ‘aromatic cage’ (formed by Tyr398 and Tyr435 in 
MAO B)25,26 is absent in renalase, where the two aromatic residues are replaced by Gln292 
and Asn323 (Fig. 6B). 
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Discussion 
The functional part of the study on renalase here described had two main purposes: (i) 
assessing the prosthetic group key chemical features that allow flavoprotein classification, 
and (ii) analyzing the interaction of renalase with nicotinamide dinucleotides, as conceivable 
cosubstrates of the enzyme. Concerning the first question, here we show that renalase 
provides a mild stabilization of the neutral form of the flavin semiquinone and that the 
renalase-bound FAD forms a sulfite-adduct, although slowly and with low affinity. Both 
features do not classify renalase as a MAO-like enzyme. Moreover, lack of stabilization for 
the FAD anionic semiquinone, and the previous observation that renalase reacts with O2 
producing the superoxide anion rather than hydrogen peroxide,8 indicate that renalase is 
probably not even an oxidase. 
As far as the second question is concerned, we confirm that renalase catalyzes 
NAD(P)H-dependent diaphorase reactions, as recently reported by others.8 In addition, we 
provide evidence for direct HT from NAD(P)H to the enzyme, and for 1:1 complex formation 
with the oxidized dinucleotides and a NADP analog. However, the exceedingly low kcat and 
kcat/Km values observed in the steady state reactions, confirmed by very slow HT in the 
reductive half reaction and millimolar affinity of the enzyme for NAD(P)+, strongly suggest 
that NADH and NADPH are not renalase physiological substrates. Such conclusion is in line 
with the absence of an evident NAD(P)-binding site in the enzyme three-dimensional 
structure. Since PHBH, which shares the same general fold of renalase, is known to bind 
NADPH (unconventionally) at the protein surface in a groove crossing the FAD cavity,27,28 
we employed molecular modeling, to assess whether renalase could accommodate NADPH in 
a similar way. Our structural comparisons indicate that FAD is much more deeply buried 
inside renalase than inside PHBH, making the putative NADPH-binding site sterically 
13 
blocked in renalase. Thus, whereas NADPH can access the FAD isoalloxazine ring of PHBH 
with limited conformation changes, a similar NADPH binding mode would appear 
catalytically unproductive in renalase. To explain the slow reactivity of renalase towards 
NAD(P)H, we speculated that nicotinamide dinucleotides might access FAD through the 
putative substrate-binding cavity. 
A further point that needs to be discussed is the recent report that the Glu37 allelic 
variant of the protein displays higher catalytic efficiency (kcat/Km
NADH) in the reductase 
reaction, relative to the Asp37 form.8 The crystal structure of the protein here described 
shows that residue 37 is located in a surface loop at the interface between the two domains, 
far from the active site. Moreover, consistent with structural evidences, we found no 
difference between the diaphorase activity of the two allelic variants of the enzyme. This 
discrepancy could be ascribed to the fact that we isolated renalase forms that underwent 
folding and FAD incorporation within E. coli cells,15 while catalytic differences between 
variants were detected on proteins that were refolded in vitro.8 Indeed, it has been shown that 
in vitro refolding may results in significant alterations of the properties of flavoproteins.29 
In conclusion, the structural data firstly here reported are in keeping with the results of 
our previous and current functional studies pointing out that renalase is not a MAO and most 
probably not an oxidase. On the other hand, structural comparisons of renalase with its 
homologs do not allow to shed additional light on the reaction catalyzed by this enzyme. 
Taken together, our observations suggest that the substrate of renalase may be a large polar 
molecule, possibly carrying a negative charge; the chemical process catalyzed by renalase on 
such substrate would be different from an oxidase reaction. 
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Materials and Methods 
NAD+, NADP+, NADH, NADPH, 2’-phospho-AMP, 5’-AMP, INT and WST1 were 
purchased from Sigma-Aldrich. 
 
Renalase expression and purification 
The variant of human renalase carrying Asp at position 37 was produced in the Rosetta(DE3) 
E. coli strain, transformed with the pET-SUMO-RNLS.15 To obtain the other known 
widespread variant of the protein,8 a point mutation resulting in the Asp37Glu substitution 
was introduced in the renalase coding sequence of the above plasmid, using the 
QuikChange® Lightning Site-Directed Mutagenesis Kit (Stratagene), in conjunction with the 
complementary oligonucleotides 5'-GGGACAAGGCTGAGGACTCAGGGGGAAG-3' and 
5’-CTTCCCCCTGAGTCCTCAGCCTTGTCCC-3 (base changes underlined). Both 
recombinant forms of renalase were produced and purified according to the procedure 
previously reported.15 Renalase concentration was quantified on the basis of the extinction 
coefficient of 11.3 mM-1cm-1 at 457 nm.15 
 
Photoreduction experiments, ligand-binding studies and activity assays 
All spectrophotometric measurements were performed either on a 8453 diode-array (Agilent) 
or a Cary 100 double-beam (Varian) spectrophotometer. Anaerobic stepwise photoreduction 
of the renalase FAD prosthetic group was carried out using the light/EDTA system.30 
Samples of ca. 15 µM renalase in 10 mM phosphate-NaOH/10 mM pyrophosphate-NaOH, at 
pH values ranging from 5.5 to 9.5, containing 15 mM EDTA and ca. 1.5 µM deaza-
riboflavin, were brought to anaerobic conditions in a sealed cuvette by successive cycles of 
N2 flushing and application of vacuum. Spectra were recorded before and as after successive 
illumination periods, until full reduction was obtained in a total irradiation time of about 4 
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min. Sodium sulfite titration of renalase was performed in PBS at 25 °C. Spectra were 
recorded before and after successive additions of allowing the reaction to reach equilibrium 
after each increase in ligand concentration. From the time course of the spectral change 
accompanying adduct formation, the pseudo-first order rate constants of the process were 
obtained at different Na2SO3 concentrations. The secondary plot of this apparent constant as a 
function of ligand concentration yielded the individual constants for adduct formation and 
dissociation from the slope and the intercept of the plot, respectively. The putative reductive 
half-reaction catalyzed by renalase, i.e. the HT from NAD(P)H to FAD was monitored 
spectrophotometrically at 37 °C, by recording the spectra of anaerobic solutions of 5 µM 
renalase in 50 mM Tris-HCl, pH 7.2, at various reaction times after the addition of NADH or 
NADPH at different concentrations. Spectrophotometric active-site titrations of renalase with 
NADP+ , NAD+, 2’-P-AMP, or 5’-AMP were carried out at 25 °C in 50 mM Tris-HCl, pH 
7.4, according to the procedure described elsewhere.31 NADH- and NADPH-dependent 
diaphorase activities of renalase were assayed at 37 °C in 50 mM Tris-HCl, pH 7.2, using a 
fixed concentration of either 100 µM INT or 500 µM WST1 as electron acceptors. The 
reaction mixture included 2.6 M renalase and a variable concentration of reduced 
dinucleotide in the range 0.05-2 mM. In the case of the INT-dependent reaction, 0.1% triton 
X-100 was also included to avoid precipitation of the formazan product. The time-course of 
the absorbance increase at the appropriate wavelength was monitored continuously and 
steady-state rates were calculated using the extinction coefficient of 18.5 mM-1cm-1 at 490 nm 
and 37 mM-1cm-1 at 450 nm for INT and WST1, respectively. 
 
Crystallization and structure solution 
Renalase crystals were obtained in sitting drop set-up, mixing 0.2 l of protein, (c = 24 
mg/ml; supplemented with freshly added 10 mM DDT) and 0.1 l of reservoir solution (30% 
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PEG 8k, 0.1 M sodium cacodylate, pH 6.5, 0.2 M ammonium sulphate). Small crystals grown 
in about five days at 20 °C, with average dimension of 50×25×25 m3. Crystals were 
transferred to a cryoprotectant solution (32% PEG 8k, 0.1 M sodium cacodylate, pH 6.5, 0.2 
M ammonium sulphate, 25% glycerol) before to be flash cooled in liquid nitrogen. 
Diffraction data were collected at ESRF beam line id23-2. The crystal, belonging to the 
monoclinic space group P21, diffracted at 2.5 Å resolution. During data collection the crystal 
suffered of radiation damage causing a reduced completeness of data (84.7%). While the 
color of crystals used for data collection indicated that bound FAD was unequivocally 
oxidized, minor/partial reduction of the coenzyme during X-ray irradiation cannot be 
excluded. The final model was of no help in revealing the oxidation state of the cofactor, 
since the two nitrogen atoms of FAD were found not involved in hydrogen bonds. Renalase 
structure was solved by molecular replacement (MR; program ‘Molrep’)32. The model used 
for MR search was built starting from the atomic coordinates of the q888a4 oxidoreductase of 
Pseudomonas syringae (a FAD-containing protein of unknown function; PDB ID: 3KKJ), 
divided into two domains: the FAD binding domain (Mod1, amino acids 2-33, 124-181, 278-
329) and the cofactor binding domain (Mod2, amino acids 82-99, 185-275), including about 
74% of the renalase residues. Since Matthews analysis suggested the presence of two 
molecules in the crystal asymmetric unit (solvent content 57%), MR search (max resolution 
3.5 Å) was performed in two subsequent steps: first to locate two copies of Mod1 (Rfac/Scor 
= 0.572/0.445) and then the remaining two copies of Mod2 (Rfac/Scor = 0.568/0.465). After 
rigid body refinement (R/Rfree 0.522/0.514) and constrained refinement (R/Rfree 
0.435/0.488; ‘Refmac’)33 we started mutating amino acids and manual rebuilding (‘Coot’)34. 
A clear electron density was present in the FAD binding site and the ligand model was 
therefore built. The programs ‘Parrot’35 and ‘Buccaneer’ were used to help modelling during 
the manual (re)building procedures, omit maps were produced to correct for errors in the 
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model, and programs ‘Refmac5’ and ‘Buster’ were used for final refinement. The final model 
contains 335 and 333 amino acids over 442, in molecules A and B, respectively, two FAD, 
three sulphate and 128 water molecules. Data collection and refinement statistics are reported 
in Table 2. Structural figures were prepared with PyMOL (http://www.pymol.org). 
 
Accession number 
The atomic coordinates of human renalase isoform 1 have been deposited in the RCSB 
Protein Data Bank with the accession code 3QJ4. 
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Figure captions 
 
Figure 1. Anaerobic photoreduction of renalase at different pH values. Progress of 
protein-bound FAD reduction as recorded on ca. 18 M renalase in 10 mM phosphate-
NaOH/10 mM pyrophosphate-NaOH, pH 6.5. The different traces represent the spectra 
recorded before (solid thin line) and as after each successive illumination periods (different 
line styles), until full reduction was obtained (solid thick line). The inset shows the maximal 
intensity reached at 600 nm in titrations carried out at different pH values. The interpolating 
line corresponds to the theoretical curve for the protonation of a single group with pKa of 7.0 
± 0.3.  
 
Figure 2. Titration of renalase with SO32- anion. Spectra of renalase in the visible region 
recorded before (solid line) and after successive additions of NaSO3 (0.5, 1.0, 2.0, 3.9, 8.8, 
18, 37 mM final concentration) showing the progressive bleaching of bound FAD. The inset 
the reports the progress of FAD-sulfite adduct formation measured as the ratio between the 
A457 measured in the presence of increasing NaSO3 concentrations and its initial value. The 
curve represents the theoretical equation for a 1:1 stoichiometry, whose fitting to the 
experimental data yielded a Kd of 1.8 ± 0.2 mM.  
 
Figure 3. Catalytic activity of renalase on NADH and NADPH. Steady-state rate of the 
NADH- and NADPH-INT reductase reactions catalyzed by renalase, as monitored at 37 °C in 
50 mM Tris-HCl, pH 7.2, are plotted as a function of reductant concentration.  
 
Figure 4. Interaction of renalase with NADP+, NAD+, and 2’-P-AMP. Approximately 20 
M renalase was titrated with either NADP+, NAD+, or 2’-P-AMP at 25 °C in 50 mM Tris-
24 
HCl, pH 7.4. Difference spectra extrapolated for ligand saturating conditions of the 
complexes of renalase with NADP+ (solid line), NAD+ (dashed line) and 2’-P-AMP (dotted 
line) are shown as extinction coefficient. In the inset the progress of the fractional amount of 
complexed protein is plotted as a function of NADP+ (filled circles), NAD+ (empty circles), 
or 2’-P-AMP (triangles) concentration. The curves represent the theoretical equation for a 1:1 
stoichiometry, whose fitting to data yielded Kd of values of 1.6 ± 0.1 mM, 2.2 ± 0.1 mM, and 
1.2 ± 0.3 mM, respectively. 
 
Figure 5. Amino acid sequence and three-dimensional structure of human renalase.  
(A) Multiple alignment of human renalase with orthologs from different organisms 
110671808, Mus musculus (73% identity); 50540280, Danio rerio (60% identity); 
193575653, Acyrthosiphon pisum (34% identity); 307154671, Cyanothece sp. (28% identity). 
Partially conserved residues are boxed, with invariant residues highlighted in red. Secondary 
structure elements are indicated above the renalase sequence. 
(B) Renalase overall three-dimensional structure with secondary structure elements as 
highlighted in panel A. The FAD binding domain in shown red, the substrate-binding domain 
in blue, and the 62-108 subdomain in green. 
 
Figure 6. Protein-FAD interactions and active-site cavity of renalase.  
(A) The overlay of the three-dimensional structure of renalase to those of its most similar 
homologs is displayed on the left. The renalase molecule is shown as a green ribbon, with the 
FAD prosthetic group displayed as a wireframe in CPK colors. The C traces of 
Exiguobacterium sp. protoporphyrinogen oxidase (PDB ID: 3LOV, blue color, rmsds 2.7 Å 
for 286 C), Rhodococcus opacus L-amino acid oxidase (PDB ID: 2JB2, brown color, rmsds 
2.5 Å for 292 C), and H. sapiens monoamine oxidase (PDB ID: 2BXR, red color, rmsds 3.0 
25 
Å for 283 C) are also shown to highlight location of the third domain that is not present in 
renalase. The molecular surface of renalase, colored according to its potential (rotated by 90° 
respect to panel A), is displayed on the right. The entry of the active-site cavity, showing the 
pyrimidine side of the isoalloxazine ring of FAD, is clearly visible. 
(B) Stereo view of the proposed renalase active-site region, showing FAD, the residues 
exchanging hydrogen bonds with FAD (green carbon atoms), the main residues lining the 
cavity above the isoalloxazine ring (blue carbon atoms), and the ordered sulphate ion bound 
at the border of the active-site cavity. 
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Tables 
 
Table 1. Kinetic parameters of renalase for the NADH- and NADPH-dependent INT 
reductase reactions.a 
Cosubstrate 
kcat 
(min-1) 
Km 
(M) 
kcat/Km 
(min-1M-1) 
NADH 0.14 18 7.8×10-3 ± 1.2×10-3 
NADPH 0.26 175 1.5×10-3 ± 1.4×10-4 
 
aINT-diaphorase activities of renalase were assayed at 37 °C in the presence of a fixed 
concentration of 100 M INT. 
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Table 2. Crystallographic data collection and structure refinement statistics. 
Data Collection Statistics 
Space group P21 
Unit-cell parameters (Å) a=53.8 Å, b=86.6 Å, c=93.2 Å, 
α=γ= 90°, β= 95.3° 
Resolution (Å) 48.4 - 2.5 
Mosaicity (°) 1.0 
№ of unique reflections 25,082 (3,770) 
Completeness (%) 84.7 (87.5) 
Redundancy 1.8 (1.8) 
Rmerge † (%) 8.8 (49.5) 
Average I/σ (I) 5.8 (1.9) 
 
Refinement Statistics 
R factor ‡ (%) 21.7 
Rfree § (%) 26.0 
r.m.s. bond lengths (Å) 0.008 
r.m.s. bond angles (°) 1.14 
  
Ramachandran Plot 
Residues in most favoured 
regions (%) 
89.3% 
Residues in additionally 
allowed regions (%) 
10.0% 
 
28 
 
 
 
 
 
Fig. 1 
 
29 
 
 
 
 
 
Fig. 2 
 
30 
 
 
 
 
 
Fig. 3 
 
31 
 
 
 
 
 
Fig. 4 
 
32 
 
 
 
 
 
Fig. 5 
 
33 
 
 
 
 
 
Fig. 6 
